论文部分内容阅读
不久前,由军事医学科学院放射医学研究所承担的国家“863”重点课题——“重组新型人肝细胞生成素的研制”正式通过专家鉴定,提前进入中试。这一成果预示,我国有可能在近期内研制成一种治疗重症肝炎的高效基因工程药物。80年代,我军医学工作者在世界上首创了用发育早期的肝细胞输注治疗重症肝炎的方法,使该病病死率降至30%以下,引起国际医学界关注。为进一步研究其治疗机理,寻找疗效成分,并最终用先进的基因工程方法生产该成分,军事医学科学院
Not long ago, the key national “863” project undertaken by the Institute of Radiological Medicine of the Academy of Military Medical Sciences - “Development of a Recombinant New Type of Human Hepatogenin” was formally approved by experts and advanced into the pilot. This result indicates that it is possible for China to develop a highly efficient genetically engineered drug for the treatment of severe hepatitis in the near future. In the 1980s, our military workers in the world pioneered the use of early development of hepatocyte infusions for the treatment of severe hepatitis and reduced the mortality rate to less than 30%, a cause of concern to the international medical community. In order to further study its mechanism of treatment, looking for therapeutic ingredients, and ultimately the use of advanced genetic engineering methods to produce the composition, the Military Academy of Medical Sciences